All Outputs (2)

Dual-acting agents for improving cognition and real-world function in Alzheimer's disease: Focus on 5-HT6 and D3 receptors as hubs (2020)
Journal Article
Millan, M. J., Dekeyne, A., Gobert, A., Brocco, M., Mannoury la Cour, C., Ortuno, J. C., …Fone, K. C. (2020). Dual-acting agents for improving cognition and real-world function in Alzheimer's disease: Focus on 5-HT6 and D3 receptors as hubs. Neuropharmacology, 177, Article 108099. https://doi.org/10.1016/j.neuropharm.2020.108099

© 2020 Elsevier Ltd To date, there are no interventions that impede the inexorable progression of Alzheimer's disease (AD), and currently-available drugs cholinesterase (AChE) inhibitors and the N-Methyl-D-Aspartate receptor antagonist, memantine, of... Read More about Dual-acting agents for improving cognition and real-world function in Alzheimer's disease: Focus on 5-HT6 and D3 receptors as hubs.

The dopamine D3-preferring D2/D3 dopamine receptor partial agonist, cariprazine, reverses behavioral changes in a rat neurodevelopmental model for schizophrenia (2015)
Journal Article
Watson, D. J., King, M. V., Gyertyán, I., Kiss, B., Adham, N., & Fone, K. C. (2016). The dopamine D3-preferring D2/D3 dopamine receptor partial agonist, cariprazine, reverses behavioral changes in a rat neurodevelopmental model for schizophrenia. European Neuropsychopharmacology, 26, https://doi.org/10.1016/j.euroneuro.2015.12.020

Current antipsychotic medication is largely ineffective against the negative and cognitive symptoms of schizophrenia. One promising therapeutic development is to design new molecules that balance actions on dopamine D2 and D3 receptors to maximise be... Read More about The dopamine D3-preferring D2/D3 dopamine receptor partial agonist, cariprazine, reverses behavioral changes in a rat neurodevelopmental model for schizophrenia.